Drug Profile
Eleclazine
Alternative Names: GS-6615Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antiarrhythmics; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Vasodilators
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertrophic cardiomyopathy; Ischaemic heart disorders; Long QT syndrome; Ventricular arrhythmias
Most Recent Events
- 27 Sep 2021 No development reported - Phase-II for Ventricular arrhythmias in USA, Netherlands, Germany, Canada, Denmark, Czech Republic, Israel, Hungary, Poland (PO)
- 27 Sep 2021 No development reported - Phase-II/III for Hypertrophic cardiomyopathy in USA, France, Germany, Italy, Netherlands, Italy, Israel, United Kingdom, United Kingdom, Australia (PO)
- 27 Sep 2021 No development reported - Phase-III for Long QT syndrome in USA, Netherlands, Spain, Italy, France, Germany, United Kingdom, Canada, Israel (PO)